i 124-evuzamitide
PeptideexperimentalImaging agent
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05235269)
Timeline
Indications
Mechanism of action
- Serum amyloid P-componentBINDING AGENT
APCS binding agent
Chemistry & pharmacology
- Imaging
- 124-iodine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06907849 | Phase 2 | May 31, 2025 | Attralus, Inc., University of Tennessee |
| NCT06788535 | Phase 3 | Jan 14, 2025 | Attralus, Inc., Harvard University |
| NCT05635045 | Phase 2 | Dec 31, 2022 | Attralus, Inc., Columbia University |
| NCT05235269 | Phase 2 | Nov 30, 2021 | Attralus, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Attralus, Inc. | For profit | 4 | 1 | 2 | 2021 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Tennessee | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1